Cracking The Code: Understanding Analyst Reviews For Ensign Group
In the latest quarter, 4 analysts provided ratings for Ensign Group (NASDAQ:ENSG), showcasing a mix of bullish and bearish perspectives.The following table provides a quick overview of their recent
Ensign Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 11% Truist Securities $135 → $150 Maintains Hold 06/28/2024 -0.84% Macquarie → $134 Initiates
JP Morgan Maintains Neutral on Alkermes, Lowers Price Target to $31
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $32 to $31.
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 31.3% JP Morgan $32 → $31 Maintains Neutral 06/17/2024 44.01% TD Cowen → $34 Initiates
Select Medical's Concentra Launches IPO for 22.5M Shares on NYSE
Select Medical Holdings Corporation ("Select Medical") (NYSE:SEM) today announced that Concentra Group Holdings Parent, Inc. ("Concentra"), a wholly owned subsidiary of Select Medical, has launched
Select Medical Holdings Shares Are Trading Lower After the Company Reported Its Subsidiary, Concentra Group Holdings Parent's, Q2 Financial Results
Select Medical Holdings Shares Are Trading Lower After the Company Reported Its Subsidiary, Concentra Group Holdings Parent's, Q2 Financial
Expert Ratings For RadNet
4 analysts have shared their evaluations of RadNet (NASDAQ:RDNT) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,
RadNet Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 -15.83% Barclays $48 → $51 Maintains Equal-Weight 05/15/2024 3.97% Truist Securities $55 → $63
10 Analysts Have This To Say About Glaukos
During the last three months, 10 analysts shared their evaluations of Glaukos (NYSE:GKOS), revealing diverse outlooks from bullish to bearish.The table below offers a condensed view of their recent
Glaukos Cut as Citi Reviews U.S. MedTechs
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
Glaukos Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 9.66% Citigroup $130 → $132 Downgrades Buy → Neutral 06/05/2024 8% Stifel $110 → $130
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,200 Today
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 19.45% on an annualized basis producing an average annual return of 32.47%. Currently, Krystal Biotech has a market c
How Is The Market Feeling About Krystal Biotech?
Krystal Biotech's (NYSE:KRYS) short percent of float has risen 7.87% since its last report. The company recently reported that it has 2.90 million shares sold short, which is 13.43% of all regular sha
Peering Into Select Medical Hldgs's Recent Short Interest
Select Medical Hldgs's (NYSE:SEM) short percent of float has risen 3.58% since its last report. The company recently reported that it has 2.15 million shares sold short, which is 3.18% of all regular
How Is The Market Feeling About Ensign Group?
Ensign Group's (NYSE:ENSG) short percent of float has fallen 3.52% since its last report. The company recently reported that it has 3.03 million shares sold short, which is 7.96% of all regular shares
$100 Invested In Ensign Group 5 Years Ago Would Be Worth This Much Today
Ensign Group (NASDAQ:ENSG) has outperformed the market over the past 5 years by 5.16% on an annualized basis producing an average annual return of 17.96%. Currently, Ensign Group has a market capitali
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...
Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.
Analyst Expectations For Merit Medical Systems's Future
Merit Medical Systems (NASDAQ:MMSI) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The following table provides a quick overview of th
Ensign Group Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 10.89% Macquarie → $134 Initiates Coverage On → Outperform 05/06/2024 11.72% Oppenheimer $130 →